Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus VITUZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus VITUZ.
KERYDIN vs VITUZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Vituz is an epidermal growth factor receptor (EGFR) inhibitor that binds to the tyrosine kinase domain, blocking downstream signaling pathways involved in cell proliferation and survival.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
400 mg orally every 8 hours for 5 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
The terminal elimination half-life is 12-15 hours in patients with normal renal function, allowing twice-daily dosing. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to 20-28 hours; in severe impairment (CrCl <30 mL/min), it exceeds 40 hours.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
VITUZ (vitluzolamide) is primarily excreted via renal elimination as unchanged drug (45-55%) and as the major inactive metabolite M1 (20-30%). Biliary/fecal excretion accounts for 15-20%, primarily as M1. Less than 5% is eliminated via other routes.
Category C
Category C
Antifungal
Antifungal